Division of Gastroenterology and the Inflammatory Bowel Diseases Center, Washington University School of Medicine, St. Louis, Missouri.
Cancer Res. 2019 Mar 15;79(6):1138-1150. doi: 10.1158/0008-5472.CAN-18-0668. Epub 2019 Jan 24.
The tryptophan-metabolizing enzyme indoleamine 2,3 dioxygenase 1 (IDO1) is frequently overexpressed in epithelial-derived malignancies, where it plays a recognized role in promoting tumor immune tolerance. We previously demonstrated that the IDO1-kynurenine pathway (KP) also directly supports colorectal cancer growth by promoting activation of β-catenin and driving neoplastic growth in mice lacking intact adaptive immunity. In this study, we sought to delineate the specific role of epithelial IDO1 in colon tumorigenesis and define how IDO1 and KP metabolites interact with pivotal neoplastic signaling pathways of the colon epithelium. We generated a novel intestinal epithelial-specific IDO1 knockout mouse and utilized established colorectal cancer cell lines containing β-catenin-stabilizing mutations, human colorectal cancer samples, and human-derived epithelial organoids (colonoids and tumoroids). Mice with intestinal epithelial-specific knockout of IDO1 developed fewer and smaller tumors than wild-type littermates in a model of inflammation-driven colon tumorigenesis. Moreover, their tumors exhibited reduced nuclear β-catenin and neoplastic proliferation but increased apoptosis. Mechanistically, KP metabolites (except kynurenic acid) rapidly activated PI3K-Akt signaling in the neoplastic epithelium to promote nuclear translocation of β-catenin, cellular proliferation, and resistance to apoptosis. Together, these data define a novel cell-autonomous function and mechanism by which IDO1 activity promotes colorectal cancer progression. These findings may have implications for the rational design of new clinical trials that exploit a synergy of IDO1 inhibitors with conventional cancer therapies for which Akt activation provides resistance such as radiation. This study identifies a new mechanistic link between IDO1 activity and PI3K/AKT signaling, both of which are important pathways involved in cancer growth and resistance to cancer therapy.
色氨酸代谢酶吲哚胺 2,3 双加氧酶 1(IDO1)在上皮源性恶性肿瘤中经常过表达,在促进肿瘤免疫耐受中发挥公认作用。我们之前证明 IDO1-犬尿氨酸途径(KP)也通过促进β-连环蛋白的激活并在缺乏完整适应性免疫的小鼠中驱动肿瘤生长,直接支持结直肠癌的生长。在这项研究中,我们试图描绘上皮 IDO1 在结肠肿瘤发生中的特定作用,并确定 IDO1 和 KP 代谢物如何与结肠上皮的关键肿瘤信号通路相互作用。我们生成了一种新型的肠道上皮细胞特异性 IDO1 敲除小鼠,并利用含有β-连环蛋白稳定突变的已建立的结直肠癌细胞系、人结直肠癌样本和人衍生的上皮类器官(类肠和类肿瘤)。在炎症驱动的结肠肿瘤发生模型中,肠道上皮细胞特异性 IDO1 敲除的小鼠比野生型同窝小鼠发展出更少和更小的肿瘤。此外,它们的肿瘤表现出核β-连环蛋白减少和肿瘤增殖增加以及凋亡增加。从机制上讲,KP 代谢物(除了犬尿氨酸酸)迅速激活肿瘤上皮中的 PI3K-Akt 信号通路,以促进β-连环蛋白的核易位、细胞增殖和对凋亡的抵抗。总的来说,这些数据定义了 IDO1 活性促进结直肠癌进展的新的自主细胞功能和机制。这些发现可能对合理设计新的临床试验具有重要意义,这些临床试验利用 IDO1 抑制剂与 Akt 激活提供耐药性的常规癌症疗法(如辐射)之间的协同作用。这项研究确定了 IDO1 活性与 PI3K/AKT 信号之间的新的机制联系,这两者都是涉及癌症生长和对癌症治疗耐药性的重要途径。